Supplemental-Figures-and-Legends from Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition
Year: 2023
Type: supplementary-materials
Abstract: All Supplementary Figures: Fig S1: Major subtypes in 1215 pediatric cancers. Fig S2: Frequency of protein coding point mutations in 1215 pediatric tumors. Fig S3: Confirmatory tissue specific preferences for MAPK pathway mutations in cBioPortal CRCs and gliomas. Fig S4: Unsupervised clustering of CMMRD tumors, normal fetal brain, and normal adult brain based on RNA-sequencing. Fig S5: Phospho-ERK immunohistochemical staining of hypermutant RRD brain and CRCs. Fig S6: Genomic characterization and treatment of 3 CRC MMRD cell lines with Trametinib. Fig S7: Combination anti-PD1 and MEKi promotes an anti-tumor immune response.
Authors: Brittany B. Campbell, Melissa A. Galati, Simone C. Stone, Alexandra N. Riemenschneider, Melissa Edwards, Sumedha Sudhaman, Robert Siddaway, Martin Komosa, Nuno M. Nunes, Liana Nobre, A. Sorana Morrissy, Matthew Zatzman, Michal Zapotocky, Lazar Joksimovic, Sangeetha N. Kalimuthu, David Samuel, Gary Mason, Eric Bouffet, Daniel A. Morgenstern, Melyssa Aronson, Carol Durno, David Malkin, John M. Maris, Michael D. Taylor, Adam Shlien, Trevor J. Pugh, Pamela S. Ohashi, Cynthia E. Hawkins, Uri Tabori
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362560029